代理机构 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
代理人 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
主权项 |
1. An isolated or purified sophorolipid-producing cell: (A) transformed with a nucleic acid encoding an E4 polypeptide; or (B) modified to disrupt at least one endogenous gene encoding an E4 polypeptide;
wherein said E4 comprises (a) the amino acid sequence of SEQ ID NO: 9; or (b) a variant of the amino acid sequence of SEQ ID NO: 9 which is identical to the amino acid sequence of SEQ ID NO: 9 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 9 have been modified by deletion, substitution, and/or insertion, wherein the E4 polypeptide has the ability to catalyze the conversion of:
(i) 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid 1′,4″-lactone and acetyl-coenzyme A into 17-L-[(2′-O-β-D-glucopyranosyl-β-D- glucopyranosyl)oxy]-Z-9-octadecenoic acid 1′,4″-lactone monoacetate;(ii) 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid 1′,4″-lactone monoacetate and acetyl-coenzyme A into 17-L-[(2′-O-β-D -glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid 1′,4″-lactone diacetate; or(iii) 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid ′,4″-lactone and acetyl-coenzyme A into 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl) oxy]-Z-9-octadecenoic acid 1′,4″-lactone diacetate; wherein said cell may optionally contain a nucleic acid encoding at least one E1, E2, E3 or E5 polypeptide or wherein said cell may optionally have a disruption in an endogenous gene encoding an E3 polypeptide; wherein: E1 comprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 53, 55, 57, 59, 61 and 63; or (b) a variant of the amino acid sequence of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 which is identical to SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 7, 53, 55, 57, 59, 61 or 63 have been modified by deletion, substitution, and/or insertion; wherein the E1 polypeptide catalyzes the conversion of Z-9-octadecenoic acid into 17-hydroxy-Z-9-octadecenoic acid; E2 comprises (a) an amino acid sequence selected from the group consisting of SEQ ID NO: 8 and 11; or (b) a variant of the amino acid sequence of SEQ ID NO: 8 or 11 which is identical to the amino acid sequence of SEQ ID NO: 8 or 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 8 or 11 have been modified by deletion, substitution, and/or insertion, wherein the E2 polypeptide catalyzes the conversion of UDP-glucose and 17-hydroxy-Z-9-octadecenoic acid into 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid; E3 comprises (a) the amino acid sequence of SEQ ID NO: 11; or (b) a variant of the amino acid sequence of SEQ ID NO: 11 which is identical to the amino acid sequence of SEQ ID NO: 11 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 11 have been modified by deletion, substitution, and/or insertion, wherein the E3 polypeptide has the ability to catalyze the conversion of 17-(β-D-glucopyranosyloxy)-Z-9-octadecenoic acid and UDP-glucose into 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-Z-9-octadecenoic acid; and E5 comprises (a) the amino acid sequence of SEQ ID NO: 10; or (b) a variant of the amino acid sequence of SEQ ID NO: 10 which is identical to the amino acid sequence of SEQ ID NO: 10 except that at least one residue up to 5% of the amino acid residues of SEQ ID NO: 10 have been modified by deletion, substitution, and/or insertion, wherein the E5 polypeptide has the ability to transfer a sophorolipid out of the sophorolipid-producing cell into the surrounding medium. |